

# Considerations for ISO 11608:2022

**Alan Stevens**

Assistant Director, Injection Devices Team

Division of Drug Delivery and

General Hospital Devices and Human Factors

OHT3/OPEQ/CDRH

November 2022

# Highlights of 11608 Updates

**Primary Functions (PF)**

**Combined Preconditioning Testing**

**On-body delivery systems (11608-6)**

Strengthens design controls and risk management requirements

Human factors




# ISO 11608:2022, FDA Recognition

- ISO 11608:2022 is currently recognized
- Transition period for prior versions ends July 9, 2023

# Primary Function: Definition


- function or operation of the needle-based injection system, which, if it does not perform to specifications during use, would directly result in a failure to accurately deliver the medicinal product via the correct route and/or directly result in unacceptable harm to the patient

# Primary Function



# Testing Requirements

- Primary functions shall be assessed in accordance with Table 3 conditions and preconditions based on the system designation
- Table 3 – Test Case Matrix
- Annex H (informative), provides example primary functions





PF = EPIR?

**Examples from 11608**

- **Failure of Sterile Barrier**
- **Cap Removal Force**



# Combined Preconditioning

- 11608-1 references considerations for combining preconditions prior to performance testing
  - 10.2.3 Life-cycle testing
  - 10.3.7 Transport
  - 10.3.8 Functional stability
  - Annex A.3.1
- 11608-1 – preconditions should be combined if, per risk assessment, high probability of exposure during normal use
- FDA recommends combining preconditions for emergency use products

# 11608-6, On-body Delivery Systems

- Testing requirements in addition to ISO 11608-1
  - In-use conditions
  - Physical/functional assessment of injection pathway (e.g. needle/cannula)
  - Adhesion
  - Occlusion
  - Dosing Requirements (accuracy, time, profile)

